All In Biotech

Drug Trial Radar · NCT05495204

External Comparison of Ibalizumab in Trials vs. Other Regimens in OPERA

External Comparison of Effectiveness of Ibalizumab in Clinical Trials vs. Other HTE Regimens in OPERA

Last checked: Nov 19, 2026Latest source record: Sep 7, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

141

Actual

Start

Aug 5, 2022

Primary completion

Feb 20, 2023

Study completion Feb 20, 2023

Sponsor

Lead sponsor
EpividianIndustry
Sponsor type
Industry
Collaborators
Theratechnologies; FIECON
First posted
Aug 10, 2022

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Among heavily treatment experienced people living with HIV, the virologic effectiveness of ibalizumab + optimized background regimen from two clinical trials will be compared to non-ibalizumab-containing regimens in routine clinical care in the OPERA cohort.

Conditions

  • HIV-1-infection

Interventions

  • IbalizumabDrug

    Participation in clinical trials vs. routine care in OPERA

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Viral suppressionTime frame: Week 24
  2. Viral suppressionTime frame: Week 48
  3. Viral suppressionTime frame: Week 60
  4. Viral suppressionTime frame: Week 96
  5. Viral undetectabilityTime frame: Week 24
  6. Viral undetectabilityTime frame: Week 48
  7. Viral undetectabilityTime frame: Week 60
  8. Viral undetectabilityTime frame: Week 96

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Epividian

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.